[go: up one dir, main page]

DK200100402A - Process for removing desmethyl citalopram from a citalopram product - Google Patents

Process for removing desmethyl citalopram from a citalopram product Download PDF

Info

Publication number
DK200100402A
DK200100402A DK200100402A DKPA200100402A DK200100402A DK 200100402 A DK200100402 A DK 200100402A DK 200100402 A DK200100402 A DK 200100402A DK PA200100402 A DKPA200100402 A DK PA200100402A DK 200100402 A DK200100402 A DK 200100402A
Authority
DK
Denmark
Prior art keywords
citalopram
amide
crude
product
formula
Prior art date
Application number
DK200100402A
Other languages
Danish (da)
Inventor
Dancer Robert
Villa Marco
Sbrogio Federico
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Priority to DK200100402A priority Critical patent/DK174018B1/en
Application granted granted Critical
Publication of DK174018B1 publication Critical patent/DK174018B1/en
Publication of DK200100402A publication Critical patent/DK200100402A/en

Links

Landscapes

  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

The present invention relates to a process for removing desmethylcitalopram having the formula <IMAGE> from a crude product containing citalopram having the formula <IMAGE> which process comprises subjecting the crude citalopram product containing the desmethylcitalopram impurity to a preliminary purification, where appropriate, and subsequently treating the crude product with an agent which forms an amide or an amide-like group, after which the reaction mixture is subjected to an acid/base wash and/or crystallization and recrystallization of the citalopram for the purpose of removing the amides which have been formed in the crude citalopram mixture; and the resulting citalopram product is purified further, where appropriate, and worked-up and isolated as the base or a pharmaceutically acceptable salt thereof.

Description

reaktionblandingen underkastes derefter en syre/base vask og/eller krystallisering og rekrystallisering af citalopram for at fjerne amiderne, dannet i den rå citalopramblanding; og det fremkomne citalopramprodukt renses eventuelt yderligere, oparbejdes og isoleres som basen eller et farmaceutisk acceptabelt salt deraf.the reaction mixture is then subjected to an acid / base wash and / or crystallization and recrystallization of citalopram to remove the amides formed in the crude citalopram mixture; and the resulting citalopram product is optionally further purified, worked up and isolated as the base or a pharmaceutically acceptable salt thereof.

KRAVREQUIREMENTS

1. En fremgangsmåde til fjernelse af desmethyl citalopram med formlenA process for removing desmethyl citalopram of the formula

Figure DK200100402AD00031

VIII) fra et råt produkt indeholdende citalopram med formlenVIII) from a crude product containing citalopram of the formula

Figure DK200100402AD00032

(I) omfattende eventuelt at underkaste det rå citalopramprodukt indeholdende desmethylcitalopram urenheden en indledende rensning og efterfølgende at behandle det rå produkt med et middel, der danner en amid eller en amid-lignende gruppe, valgt blandt midlerne med formlerne (a), (b) eller (c):(I) comprising optionally subjecting the crude citalopram product containing the desmethylcitalopram impurity to initial purification and subsequently treating the crude product with an agent forming an amide or an amide-like group selected from the agents of formulas (a), (b) or (c):

Figure DK200100402AD00033

hvor X er halogen eller en gruppe O-CO-R’, Hal er halogen, Y er O eller S, W er O, NH eller S og R, R’, R” og R’” hver især vælges blandt gruppen bestående af hydrogen, alkyl og eventuelt substitueret aryl eller aralkyl; reaktionblandingen underkastes derefter en syre/base vask og/eller krystallisering og rekrystal li sering af citalopram for at fjerne amiderne, dannet i den rå citalopramblanding; og det fremkomne citalopramprodukt renses eventuelt yderligere, oparbejdes og isoleres som basen eller et farmaceutisk acceptabelt salt deraf.wherein X is halogen or a group O-CO-R ', Hal is halogen, Y is O or S, W is O, NH or S and R, R', R 'and R' 'are each selected from the group consisting of hydrogen, alkyl and optionally substituted aryl or aralkyl; the reaction mixture is then subjected to an acid / base wash and / or crystallization and recrystallization of citalopram to remove the amides formed in the crude citalopram mixture; and the resulting citalopram product is optionally further purified, worked up and isolated as the base or a pharmaceutically acceptable salt thereof.

2. En fremgangsmåde ifølge krav 1, hvori det rå citalopram produkt fremstilles ved at underkaste en forbindelse med formlen ΠA process according to claim 1, wherein the crude citalopram product is prepared by subjecting a compound of formula Π

Figure DK200100402AD00041

(Π) hvori Z er iod, brom, chlor eller CF3-(CF2)n-S02-0-, hvor n er 0,1, 2, 3,4,5, 6, 7 eller 8, en cyanidudskiftningsreaktion med en cyanidkilde.(Π) wherein Z is iodine, bromine, chlorine or CF3 - (CF2) n-SO2-0-, where n is 0.1, 2, 3,4,5, 6, 7 or 8, a cyanide replacement reaction with a cyanide source .

3. Processen ifølge krav 1-2 kendetegnet ved, at midlet, der danner et amid eller en amidlignende gruppe, er et middel med formlen R-CO-X, hvori R og X er som defineret i krav 1.The process according to claims 1-2, characterized in that the agent forming an amide or an amide-like group is an agent of the formula R-CO-X, wherein R and X are as defined in claim 1.

4. Processen ifølge krav 3 kendetegnet ved, at midlet, der danner et amid eller en Amid-lignende gruppe, er et carboxylsyreanhydrid eller acylhalogenid.The process according to claim 3, characterized in that the agent forming an amide or an amide-like group is a carboxylic anhydride or acyl halide.

5. Processen ifølge krav 4 kendetegnet ved, at midlet, der danner et amid eller en amid-lignende gruppe, er et eddikesyreanhydrid 6. Processen ifølge krav 4 kendetegnet ved, at midlet, der danner et amid eller en amid-lignende gruppe, er et acylchlorid, fortrinsvis acetylchlorid.The process according to claim 4 characterized in that the agent forming an amide or an amide-like group is an acetic anhydride 6. The process according to claim 4 characterized in that the agent forming an amide or an amide-like group is an acyl chloride, preferably acetyl chloride.

7. Processen ifølge et hvilket som helst af kravene 2-6 kendetegnet ved, at Z er Br og cyanidreaktionen udføres ved en reaktion med kobbercyanid i et passende opløsningsmiddel.The process according to any one of claims 2-6, characterized in that Z is Br and the cyanide reaction is carried out by a reaction with copper cyanide in a suitable solvent.

8. Processen ifølge et hvilket som helst af kravene 2-6 kendetegnet ved, at Z er iod, brom, chlor eller CF3-(CF2)n-S02-0-, hvor n er 0,1,2,3,4, 5,6,7 eller 8, og cyanidudskiftningsreaktionen udføres med en cyanidkilde i nærvær af en palladiumkatalysator og en katalytisk mængde af Cu+ eller Zn2^.The process according to any one of claims 2-6, characterized in that Z is iodine, bromine, chlorine or CF3- (CF2) n -SO2-0-, where n is 0,1,2,3,4, 5,6,7 or 8, and the cyanide replacement reaction is carried out with a cyanide source in the presence of a palladium catalyst and a catalytic amount of Cu + or Zn 2

9. Processen ifølge i hvilket som helst af kravene 2-6 kendetegnet ved, at Z er iod, brom, chlor eller CF3-(CF2)n-S02-0-, hvor n er 0,1, 2, 3,4, 5, 6, 7 eller 8, og cyanidudskifningsreaktionen udføres ved reaktion med Zn(CN)2 i nærvær af en palladiumkatalysator.The process according to any one of claims 2-6, characterized in that Z is iodine, bromine, chlorine or CF3- (CF2) n -SO2-0-, where n is 0.1, 2, 3.4, 5, 6, 7 or 8 and the cyanide exchange reaction is carried out by reaction with Zn (CN) 2 in the presence of a palladium catalyst.

10. Processen ifølge krav 9 kendetegnet ved, at Z er Br.The process according to claim 9, characterized in that Z is Br.

11. Processen ifølge et hvilket som helst af kravene 2-6 kendetegnet ved, at Z er Cl eller Br og at cyanidudskiftningsreaktionen udføres med en cyanidkilde i nærvær af en nikkelkatalysator, eventuelt i nærvær af en katalytisk mængde af Cu+ eller Zn2+.The process according to any of claims 2-6, characterized in that Z is Cl or Br and the cyanide exchange reaction is carried out with a cyanide source in the presence of a nickel catalyst, optionally in the presence of a catalytic amount of Cu + or Zn2 +.

12. Processen ifølge krav 11 kendetegnet ved, at Z er Cl.The process according to claim 11, characterized in that Z is Cl.

DK200100402A 2000-12-22 2001-03-08 Process for removing desmethylcitalopram from a citalopram product DK174018B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DK200100402A DK174018B1 (en) 2000-12-22 2001-03-08 Process for removing desmethylcitalopram from a citalopram product

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DK200001929 2000-12-22
DKPA200001929 2000-12-22
DK200100402 2001-03-08
DK200100402A DK174018B1 (en) 2000-12-22 2001-03-08 Process for removing desmethylcitalopram from a citalopram product

Publications (2)

Publication Number Publication Date
DK174018B1 DK174018B1 (en) 2002-04-22
DK200100402A true DK200100402A (en) 2002-04-22

Family

ID=26068932

Family Applications (1)

Application Number Title Priority Date Filing Date
DK200100402A DK174018B1 (en) 2000-12-22 2001-03-08 Process for removing desmethylcitalopram from a citalopram product

Country Status (1)

Country Link
DK (1) DK174018B1 (en)

Also Published As

Publication number Publication date
DK174018B1 (en) 2002-04-22

Similar Documents

Publication Publication Date Title
JP3798982B2 (en) Method for producing pure citalopram
JP2014514292A (en) Reductive amination process for producing dronedarone using amine intermediate compounds
JP2014514291A (en) Method for producing dronedarone by mesylation
JP2004256490A (en) Method for producing trans-cyclohexane derivative
TW202000643A (en) Process for the preparation of a nitric oxide donating prostaglandin analogue
DK200100402A (en) Process for removing desmethyl citalopram from a citalopram product
JP2018502164A (en) Preparation of indamine amine derivatives and novel synthetic intermediates
JP2004323433A (en) Method for producing 5&#39;-acyloxy nucleoside compound
CA2930089C (en) Fingolimod hydrochloride process
JP3059007B2 (en) Method for producing 1- (2-carboxyphenyl) indazole derivative
JP2706554B2 (en) 4-trifluoromethylaniline derivative and method for producing the same
JP2007023005A (en) Method of manufacturing milnacipran hydrochloride
JP2004231521A (en) Method for synthesizing 3-chloro-5-nitrotoluene
KR20180101396A (en) Process for producing acid halide solution and process for producing monoester compound
EP0628024A4 (en) Synthesis of ioversol using a minimal excess of acetoxyacetylchloride.
JP2608761B2 (en) Method for producing 7-bromo-β-carboline derivative and intermediate thereof
JPH05221947A (en) Production of cyclopropane derivative
JPH0625208A (en) Reagent for resolving racemic modification, its production and its use
JP2003261559A (en) How to make esculetin
JP2004292374A (en) Method for producing carboxylic acid halide
JPH0662539B2 (en) Method for producing 2,3-dicyano-1,4-dihydroxynaphthalene derivative
JPS6213338B2 (en)
CS252794B1 (en) A method for purifying 2,6-dichlorodiphenylamine
JP2001328993A (en) Optically active phosphine compound
JP2015196668A (en) Method for manufacturing cyanopyridine compound

Legal Events

Date Code Title Description
B1 Patent granted (law 1993)
PBP Patent lapsed

Ref document number: DK